Berlin-born AMBOSS, a knowledge platform for medical professionals, has raised a €30 M Series B to fuel its international rollout and app development. Investment firms Partech and Target Global led the round, with support from existing investors Cherry Ventures, Wellington Partners, and Holtzbrinck Digital.
Since its last funding in 2017, AMBOSS has evolved from an exam preparation tool for German medical students to a global platform for doctors, giving more than 500,000 users access to the latest medical knowledge. Institutions around the world are using AMBOSS to support doctors and medical students, including two of the largest hospital groups in Europe and more than 50 medical schools, including the New York University School of Medicine (NYU).
In addition to rolling out the platform worldwide, the medtech company will use the funds to further invest in its smart guidance application, which provides evidence-based information to help clinicians make decisions at the point of care. Benedikt Hochkirchen, co-CEO of AMBOSS said, “Medical knowledge is exploding and it is almost impossible for doctors to quickly obtain reliable clinical information. Our mission is to connect every doctor with precise medical knowledge to provide the best possible care. This new funding will allow us to make a meaningful contribution to global health.”
Omri Benayoun, General Partner at Partech commented: ”Better-structured medical knowledge is the foundation to improve healthcare. Physicians and students work in a time-constrained environment, where knowledge sources are proliferating, and are often complex to access and apply. At AMBOSS, software engineers, doctors, and scientists leverage technology to bring simplicity to medical knowledge modelling and delivery. We are impressed by the unique cutting-edge approach of AMBOSS to pioneer faster breakthroughs and are excited to partner with the visionary and passionate team, which is impacting global health positively.”